Shionogi Files Antiviral NDA In China, Eyes Wider Use
Competes with Pfizer's Paxlovid Upon Approval
Undeterred by recent home turf setback, Japanese drug maker Shionogi rides a China’s policy tailwind and bets on Chinese approval for its antiviral COVID drug.
